A cancer-focused startup founded by one of the biotech industry’s leading investors is being acquired for $67 million — roughly two-thirds of what the Cambridge-based company made in its 2018 IPO.

German biotech BioNTech is buying Neon Therapeutics (Nasdaq: NTGN), according to a press release issued Thursday. BioNTech’s chief executive indicated the German drugmaker will continue Neon’s work in melanoma, ovarian and pancreatic cancers. 

“This acquisition fits with our strategy to expand…

Boston Biz Journal https://www.bizjournals.com/boston/news/2020/01/16/german-biotech-snaps-up-struggling-third-rock.html?ana=RSS&s=article_search